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Abstract
Background: Although the use of TNF inhibitors has fundamentally changed the way rheumatoid arthritis (RA) is treated,
not all patients respond well. It is desirable to facilitate the identification of responding and non-responding patients prior
to treatment, not only to avoid unnecessary treatment but also for financial reasons. In this work we have investigated the
transcriptional profile of synovial tissue sampled from RA patients before anti-TNF treatment with the aim to identify
biomarkers predictive of response.
Methodology/Principal Findings: Synovial tissue samples were obtained by arthroscopy from 62 RA patients before the
initiation of infliximab treatment. RNA was extracted and gene expression profiling was performed using an in-house
spotted long oligonucleotide array covering 17972 unique genes. Tissue sections were also analyzed by immunohisto-
chemistry to evaluate cell infiltrates. Response to infliximab treatment was assessed according to the EULAR response
criteria. The presence of lymphocyte aggregates dominated the expression profiles and a significant overrepresentation of
lymphocyte aggregates in good responding patients confounded the analyses. A statistical model was set up to control for
the effect of aggregates, but no differences could be identified between responders and non-responders. Subsequently, the
patients were split into lymphocyte aggregate positive- and negative patients. No statistically significant differences could
be identified except for 38 transcripts associated with differences between good- and non-responders in aggregate positive
patients. A profile was identified in these genes that indicated a higher level of metabolism in good responding patients,
which indirectly can be connected to increased inflammation.
Conclusions/Significance: It is pivotal to account for the presence of lymphoid aggregates when studying gene expression
patterns in rheumatoid synovial tissue. In spite of our original hypothesis, the data do not support the notion that
microarray analysis of whole synovial biopsy specimens can be used in the context of personalized medicine to identify
non-responders to anti-TNF therapy before the initiation of treatment.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
affecting the synovial tissue in multiple joints. RA is characterized
by an influx of inflammatory cells, which leads to hyperplasia and
eventually destruction of cartilage and bone [1]. RA is a
heterogeneous disease with differences in both disease progression
and genetic background of individual patients [2,3]. The advent of
TNF antagonists has revolutionized the treatment of RA, although
not all patients respond well [4]. Identification of non-responders
is important, not only because anti-TNF treatment elevates the
risk for adverse events such as infections [5], but also for financial
reasons. Therefore, we previously hypothesized that synovial tissue
analysis might be used to predict the response to anti-TNF
therapy. Several different approaches have been undertaken in
order to predict response to anti-TNF treatment in RA patients,
but low success rate leaves room for improvements
[6,7,8,9,10,11,12]. Three studies have performed expression
analysis with microarrays using RNA extracted from peripheral
blood monocytes (PBMCs) with the purpose of predicting response
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responders and non-responders before treatment [14]. Although
the results appeared promising only one of the 20 transcripts was
verified by real-time PCR as significant between responders and
non-responders at baseline, and previous lack of stability of
microarray classifiers [16] warrants verification in an independent
study. Previously, microarray technology was also applied on serial
synovial biopsies in a study of 10 RA patients to investigate the
effects of infliximab treatment on the transcriptional profile with
promising results [17]. In another study transcriptional profiling
was performed on synovial biopsies obtained at baseline from 18
RA patients before treatment with infliximab [18]. Several
biological processes related to inflammation were correlated to a
better clinical response. In contrast, another study in 25 RA
patients identified a signature of 439 genes mainly associated with
cell division and immune response pathways to be associated with
the clinical response to adalimumab treatment [19]. Taken
together, results of different studies have been variable. Moreover,
although differences on the group levels have been suggested,
there has been no convincing evidence that this approach could be
helpful in predicting clinical response reliably in individual
patients. To further investigate whether the molecular signature
at baseline could be used to predict the clinical response to anti-
TNF therapy in the context of personalized medicine, we
performed transcriptional profiling of whole synovial biopsies




The Medical Ethics Committee of the Academic Medical
Center, University of Amsterdam approved the protocol. All
patients gave written informed consent.
Patients
The patients participated in a previously described prospective
study [10]; we selected patients from the original cohort based on
the presence of sufficient synovial tissue to allow microarray
analysis. All patients fulfilled the ACR (American College of
Rheumatology) criteria for RA [20], had failed at least two disease-
modifying antirheumatic drugs (DMARDs) including methotrex-
ate (MTX), and had a disease activity score evaluated in 28 joints
(DAS28) $3.2 when included in the study. Patients were on stable
maximal tolerable MTX treatment (5–30 mg/week). The use of
non-steroidal anti-inflammatory drugs (NSAIDs) and oral corti-
costeroids (#10 mg/day) was allowed if stable for at least one
month prior to baseline. Concomitant medication was kept stable
throughout the study. Previous use of a TNF blocking agent was
an exclusion criterion. Baseline characteristics of the patients are
given in table 1.
Treatment and evaluation of clinical response
Patients were treated with infliximab, a commercial antibody
marketed by Schering-Plough. There are no patents, marketed
products, or products in development related to this research.
Also, the use of infliximab does not alter the adherence of this
work to all the PLoS ONE policies on sharing data and materials.
Infliximab was given in a dosage of 3 mg/kg intravenously at
baseline, week 2, 6, and subsequently every 8 weeks. The DAS28
was assessed at baseline, week 4, 8, 12, and 16 by skilled research
nurses. Clinical response was evaluated according to the EULAR
(European League Against Rheumatism) response criteria [21] at
week 16 after initiation of infliximab treatment.
Synovial biopsy and RNA extraction
AllpatientsunderwentsynovialtissuesamplingattheAcademical
Medical Center/University of Amsterdam by needle arthroscopy of
an actively inflamed joint (knee, ankle or wrist), performed under
local anesthesia, as described previously in detail [22]. Biopsy
specimens were obtained with a 2-mm grasping forceps (Storz,
Tuttlingen, Germany) from 6 or more sites within the joint to
minimize sampling error. The biopsy specimens (15–50 mg) were
snap frozen in liquid nitrogen and homogenised in 1 ml RNA-
STAT 60TM reagent (Tel-Test, Friendswood, TX). The quality
was assured by measuring the OD260/280 ratio using a Thermo
Scientific NanoDrop 1000 spectrophotometer (Thermo Scientific,
Wilmington, DE). Samples with a ratio .1.8 were used. A separate
block of at least 6 synovial tissue samples from the same patients was
snap frozen and assessed for the presence of lymphocyte aggregates,
as described previously in detail [23]. Briefly, aggregate size was
assessed by counting the number of cells in a radius starting from an
estimated center of the aggregate (figure 1). Aggregate size was then
classified as grade 1 (1–5 cells in the radius), grade 2 (5–10 cells in
the radius), or grade 3 (.10 cells in the radius). Tissue sections with
no lymphocyte aggregates were graded as 0. Grade 2 and grade 3
aggregates were termed large lymphocyte aggregates, while grade 1
aggregates were termed small lymphocyte aggregates.
RNA reference
Universal Human Reference RNA (Stratagene, Cedar Creek,
TX) was used as reference RNA. The reference RNA was






Age (years) 55612 56613 54612 0,55




1326114 1376122 116687 0,55
Erosive
disease (%)
45 (73) 37 (77) 8 (57) 0,14
Rheumatoid factor
positive (%)
44 (71) 36 (75) 8 (57) 0,2
Anti-CCP positive (%) 46 (74) 38 (79) 8 (57) 0,1
DAS28 6,060,9 5,960,9 6,261,0 0,26
Patients global
score (0–100mm)
64621 61622 72616 0,05
ESR (mm/hr) 29618 31617 23619 0,17
C-reactive protein
(mg/dL)
16616 17616 14618 0,64
Drug treatments
Previous DMARDs 2,361,4 2,261,3 2,761,7 0,19
Methotrexate
(mg/wk)
17,768,8 17,268,8 19,368,7 0,44
Receiving
corticosteroids (%)
16 (26) 14 (29) 2 (14) 0,67
Receiving NSAIDs (%) 29 (47) 22 (46) 7 (50) 0,78
*Based on Eular response criteria.
doi:10.1371/journal.pone.0011310.t001
Gene Expression RA Infliximab
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11310amplified and labeled according to the same procedure as with the
patient material.
RNA amplification
The RNA was amplified with the RiboAmp II kit (Applied
Biosystems, Foster City, CA). 500 ng of total RNA was used as
input for the amplification for all except 7 patients. For these
patients 300–500 ng was used due to low yield in the RNA
extraction step. RNA from 18 good responding, 30 moderate
responding and 14 non-responding patients was successfully
amplified and subsequently labeled for hybridization.
Labeling and cDNA synthesis
Labeling was performed with the ULS aRNA Fluorescent
Labeling Kit (Kreatech Diagnostics, the Netherlands) that allows
for labeling of unmodified aRNA. 2 ug was used as input in the
labeling reaction.
Oligonucleotide microarray
The microarray used in this work is an in-house printed array
manufactured at the KTH core facility [24]. The spotted 70-mer
oligo nucleotides originate from version 3.03 of Operons Human
Genome Oligo Set (Operon, Huntsville, AL). The microarray
contains 35344 features (spots) representing 28948 Entrez Gene
IDs [25] of which 17972 are unique.
Hybridization
Pre-hybridization of microarray slides was previously described
[24]. Fragmentation was performed after labeling of the aRNA
with RNA fragmentation reagents AM870 (Applied Biosystems)
yielding aRNA fragment sizes of 60–200 nucleotides. The cy5 and
cy3 labeled aRNA were then pooled in equivalent amounts and
mixed with the hybridization buffer consisting of 56 SSC, 25%
formamide (Sigma-Aldrich, St. Louis, MO) 0.1% SDS, 25%
Kreablock (Kreatech Diagnostics), 10 ug herring sperm DNA
(Invitrogen, Carlsbad, CA) and 10 ug yeast tRNA (Invitrogen).
The hybridization mixture was then heat denatured in 70uC for
3 minutes and subsequently put on ice until injection in a MAUI
hybridization mixer (Biomicro, Salt Lake City, UT). The
hybridization was performed over night in the MAUI hybridiza-
tion station (Biomicro) in which the hybridization mixture is stirred
to increase sensitivity and specificity. Subsequent washing steps
were performed as previously described [26].
Figure 1. Lymphocyte aggregates. The presence of lymphocyte aggregates was assessed on anti-CD3-stained sections. Aggregates were
counted and graded by size. Aggregate size was assessed by counting the number of cells in a radius starting from an estimated center of the
aggregate. Aggregate size was then classified as grade 1 (1–5 cells in the radius [panel B]), grade 2 (5–10 cells in the radius [panel C]), or grade 3 (.10
cells in the radius [panel D]). Tissue sections with no lymphocyte aggregates were graded as 0 (panel A).
doi:10.1371/journal.pone.0011310.g001
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Scanning and image processing was performed as previously
described [24]. Briefly, the microarrays were scanned using the
Agilent G2565BA scanner (Agilent Technologies, Palo Alto, CA)
and the feature intensities were extracted using the GenePix
5.1.0.0 software (Axon Instruments, Sunnyvale, CA).
Experimental design and data analysis
All patients were hybridized in a reference design where the
referencewas always labeled with cy3 and the samples with cy5 [27].
The microarray data were analyzed in R, an environment for
statistical programming and computing [28]. Several freely available
R packages were used for low-level analysis and normalization [29]
as described previously [24,26]. SAM (Significance Analysis of
Microarrays), available as the samr package in R, was applied to
identifydifferentiallyexpressed(DE)genes[30].Since SAM does not
allow for blocking, the LIMMA (Linear Models for Microarray
Data) [31] package, present in Bioconductor [29], was applied to
control for the effect of ectopic lymphocyte aggregates when
comparing responders. Hierarchical clusters were performed using
1–thePearsoncorrelationasthedistancemeasure[32].Enrichment
analysis was carried out to identify biological themes in groups of
relevant genes [33] using the the Gene Ontology and KEGG
databases [34,35]. PAGE (Parametric Analysis of Gene set
Enrichment) was also used to test for significant pathways/categories
between response groups in the above-mentioned databases [36,37].
FDR was used to correct for multiple testing in all enrichment/
pathwayanalyses[38].InalltestsusingtheFDR,aq-value(theFDR
analog of a p-value) ,0.05 was used as a cut-off for statistical
significance. A two-sided binomial exact test was used to test for
overrepresentation of lymphoid aggregates within response groups
assuming a 0.5 chance of having an aggregate or not. The
microarray data set has been deposited at Gene Expression
Omnibus [39] under accession number GSE21537.
Results
Significance analysis of microarrays (SAM)
SAM [30] was used to query differences between response
groups prior to treatment. The followings groups were defined
according to the EULAR response criteria: good responders (G,
n=18), moderate responders (M, n=30), responders (G and M
together: R, n=48), and non-responders (N, n=14). No features
were differentially expressed (DE, q-value,0.05) between the
different response groups (G vs. N, G vs. M, M vs. N, R vs. N).
Although individual features did not reach statistical significance
between response groups, PAGE [36] disclosed GO categories
(e.g. GO:0006935, chemotaxis, q-value 5e-50; GO:0006954
inflammatory response, q-value 2e-46; GO:0045321, leukocyte
activation, q-value 3e-23) with a higher average level in G vs. N,
which indicates a general higher level of active inflammation in G.
In addition, patients were split into two cohorts based on the
presence of anti-citrullinated protein antibodies (ACPA). There
were no statistically significant differences based on the EULAR
response in either ACPA positive or negative patients. Collectively,
at the group level expression levels of genes involved in
inflammatory processes are enriched in G, but no predictive
biomarkers could be identified that could serve as surrogate
markers of response to anti-TNF treatment in individual patients.
Hierarchical cluster of patients using features with high
variation
To get an overview of the variation between samples a
hierarchical clustering was performed using features with high
variance (log2-fold change values with interquartile range .1)
independent of response group (1321 features in total, figure 2).
The patients did not cluster according to the EULAR response
criteria, but the presence of synovial lymphocyte aggregates (both
small and large) dominated the pattern of the dendrogram.
Enrichment analysis [33] was performed on the 1321 features
using the Gene Ontology (GO) and KEGG databases [34,35]
which revealed themes indicative of inflammatory disease (top GO
category, GO:0006955, Immune response, q-value 3.2e-11; top
KEGG category, 04612, Antigen processing and presentation, q-
value 2.3e-06). Thus, the synovial gene expression profile is
especially characterized by the level of cell infiltration and immune
activation.
The effect of the presence of lymphocyte aggregates
Lymphocyte aggregate data were available for 51 out of all 62
patients. The detailed description of lymphocyte aggregates in
relationship to clinical response to infliximab treatment has been
reported before in detail for the larger cohort and we have shown
that RA patients with synovial lymphocyte aggregates have on
average a better response to infliximab treatment than those with
only diffuse leukocyte infiltration [40]. In the 51 patients included
in the present study lymphocyte aggregates (small and/or large)
were detected in 11/13 (85%), 15/25 (60%), and 6/13 (46%) of G,
M and, N, respectively. Only G had a significantly higher level of
aggregates (small and/or large, binomial exact test; G, p=0.02;
M, p=0.4; N, p=1). Therefore, patients with aggregates were
tested for statistically significant differences in transcriptional
profile compared to those without aggregates, irrespective of
response group. Here, 1965 features were significantly different
between the two groups (q-value,0.05). Enrichment analysis of
the top 500 DE genes revealed relevant and significant themes
(Table 2). Since response was positively correlated to the presence
of aggregates (small and/or large, Pearson correlation, r=0.3 (p-
value: 0.04) and there were significant differences between
aggregate positive and negative patients, a linear model was set
up in LIMMA [31] to control for the effect of small and/or large
aggregates when comparing response groups responders (G vs. N,
G vs. M, M vs. N, R vs. N), after which we did not detect any
statistically significant differences. Next, we stratified the patients
based on the presence of lymphocyte aggregates (small and/or
large aggregates versus no aggregates) and examined the
relationship between transciptional profile and clinical response
to infliximab for each tissue group. The division into aggregate
positive versus negative patients markedly decreased the sample
sizes; therefore, we could only compare R to N. In all comparisons
no features were found to be DE except for 38 features comparing
G versus N in the aggregate positive group (Table S1). Enrichment
analysis revealed no significant KEGG pathways, but two GO
categories were significant (GO:0006412, translation, q-value
0.02; GO:0009058, biosynthetic process, q-value 0.02).
Discussion
The efficiency of TNF blockade might theoretically be increased
if patients can be identified who will not respond to TNF blocking
agents, before the initiation of anti-TNF therapy. In the ,30%
patient who would not receive anti-TNF therapy on the basis of a
biomarker-directed strategy, unnecessary and expensive parenteral
therapy could be withheld. In addition, therapies with a different
mechanism of action, like rituximab, abatacept, or tocilizumab
could be initiated in these patients earlier in the disease course
than according to the current treatment algorithm. The
combination of multiple markers bears most promise to improve
Gene Expression RA Infliximab
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reduce the extensive overlap in individual marker levels that exists
between responders and non-responders. Conceivably, analysis of
gene expression profiles could provide a molecular signature that
may be used to predict the response to treatment, similar to its use
to predict outcome in patients with breast cancer [41]. The study
described here was performed in 62 RA patients, which is a
marked increase in scale from previous studies using synovial
biopsies to investigate gene expression differences between
different response groups to anti-TNF treatment. The question
was if the larger number of patients would allow for the
identification of possible biomarkers that could be used in
individual patients. Of importance and in contrast to general
belief, this does not seem to be the case. Moreover, this study
identified an important confounding factor that is relevant for
studies using microarray analysis of RA synovial tissue: the
presence of lymphocyte aggregates. When clustering the patients
to get an overview of the variation between responders, the
presence of ectopic aggregates was the most discriminating
variable. Since the presence of aggregates correlated with
response, all comparisons with regard to transcriptional profile
between good, moderate and non-responders were confounded.
Recent studies have suggested that lymphocyte aggregates are not
necessarily functioning as canonical germinal centers, but may
occur as a secondary effect to chronic inflammation [23,42]. The
overrepresentation of aggregates in good responders is in line with
the earlier described relationship between synovial inflammation
and the response to infliximab treatment [10]. Considering that
aggregates were positively correlated to response and since the
largest detectable difference was between aggregates, we set up a
linear model to control for the effect of aggregates. Again, we
could not detect any significant differences. This could indicate
that different pathogenic pathways are active in aggregate positive
versus negative patients. Therefore, the patients were split into
aggregate positive and negative patients. Here 38 features were
statistically significant between good and non-responding patients
in the aggregate positive group. The enrichment analysis is not
easily explained, containing many ribosomal transcripts (the GO
categories translation and biosynthetic process were significantly
enriched). This could argue for a higher metabolism rate in good
responding patients, indicative of a higher level of inflammation,
as shown in our previous work. Taken together, the results
presented here clearly show that in microarray analysis studies of
whole RA synovium, it is critical to control for the presence of
lymphocytes aggregates, as they may represent an important
confounding factor. Moreover, the results do not support the
notion that microarray analysis of whole synovial biopsies may be
used to predict the response to anti-TNF treatment in the context
of individualized medicine. Our findings are also in agreement
with the clinical experience that the response to TNF blockade is
not a dichotomous phenomenon [43]. In fact, even so-called non-
responders may exhibit protection against joint destruction [44],
Figure 2. Hierarchical cluster of patients using features with
high variation irrespective of response group. Patients were
clustered in a hierarchical dendrogram using features with a log2-ratio
(ratio=sample intensity/reference intensity) interquartile range .1
(1321 features in total). Abbreviations in the dendrogram: PXX=Patient
number; G, =Good responder; M=Moderate responder; N=Non
responder; L+/2=presence of large lymphocyte aggregates; S+/2
presence of small aggregates. Colors in the dendrograms:
Red=patients positive for either small or large lymphocyte aggregates;
Blue=patients negative for small and large lymphocyte aggregates;
Black=patients with no lymphocyte aggregate assessment.
doi:10.1371/journal.pone.0011310.g002
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TNF therapy do not necessarily represent completely distinct
pathogenetic subsets of RA. We need to consider that transcription
analysis of synovial biopsies results in an expression profile that
originates from a mixture of cells. Future work should address the
question as to whether analysis of individual cell types derived
from the synovium might yield better predictive biomarkers.
Previous work, using immunohistochemistry, has demonstrated a
correlation between clinical response to anti-TNF treatment on
the one hand and TNF protein expression as well as expression of
cells capable of producting TNF on the other. [10]. Although the
correlation of TNF on the protein level does not automatically
entail the same distinct transcriptional patterns due to regulation
[45,46], it is conceivable that the expression profile of microdis-
sected cell populations, previously known to be correlated with
response, may provide better targets for finding predictive
biomarkers.
Supporting Information
Table S1 This table contains the 38 features that were
differentially expressed comparing good- and non-responding
patients in the aggregate positive group. The table headings are:
chip ID - the unique identifier on the microarray; q-value in
percent - the false discovery rate; log2 fold difference - the fold
change of gene expression between good vs. non-responding
patients on a log-2 scale; Entrez gene ID - an identifier from the
Entrez gene database [1]; Gene Name - an identifier from the the
Human Gene Nomenclature Database [2]. NA - not available,
displayed for features with no annotation for the column in
question.
Found at: doi:10.1371/journal.pone.0011310.s001 (0.07 MB
DOC)
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